Allergan executive Manisha Narasimhan, PhD joins Cytonus’ Board of Directors
Dr. Narasimhan’s extensive pharmaceutical and biotechnology industry experience, combined with her scientific training and capital markets experience, make her a strong addition to our Board. We look forward to her future contributions on behalf of our shareholders.
SAN DIEGO (PRWEB)
March 10, 2020
Cytonus Therapeutics Inc. today announced that Manisha Narasimhan, Ph.D. has joined Cytonus’ Board of Directors. Dr. Narasimhan is Senior Vice President of Strategic Initiatives, Portfolio Innovation and Investor Relations at Allergan, plc.
“On behalf of the Board of Directors of Cytonus, we are extremely pleased to welcome Manisha Narasimhan as an independent director,” commented Christopher Thorne, Chairman of the Board of Directors of Cytonus. “Her extensive pharmaceutical and biotechnology industry experience, combined with her scientific training and capital markets experience, make her a strong addition to our Board. We look forward to her future contributions on behalf of our shareholders.”
Dr. Narasimhan was recently ranked #1 by Institutional Investor for Best Investor Relations Professional, Best IR Team, and Best IR Program in the pharmaceuticals sector, according to the 2020 All-America Executive Team rankings. She has wide-ranging expertise as a scientist, a financial executive and a highly effective communicator. Prior to joining Allergan, Dr. Narasimhan led the investor relations group at Regeneron Pharmaceuticals. She was previously an equity research analyst covering biotechnology at Canaccord Genuity and Piper Jaffray. Dr. Narasimhan began her career as a strategic management consultant for biotechnology and life science clients at Campbell Alliance. She received her Ph.D. in molecular biology from New York University.
About Cytonus Therapeutics Inc.
Cytonus Therapeutics Inc. is a San Diego based biotech company that has developed a vast platform of proprietary immunotherapeutic products to treat a wide range of medical conditions including cancers, infectious diseases, inflammatory diseases and cognitive disorders, and to improve patient outcomes. Its proprietary Cargocyte™ technologies are next-generation biomolecular delivery devices which have numerous medical applications across unmet therapeutic areas. Cargocytes™ are engineered to safely transport a multiplicity of therapeutic payloads into difficult-to-reach targeted tissues, and can be programmed to deliver selective, potent, and controllable “off-the-shelf” therapies. Cytonus’ vast platform of therapeutics and vaccines has the potential to improve the health and lives of people with life-threatening conditions. For more information, we invite you to visit the Cytonus website at https://Cytonus.com. Please follow us on Cytonus on LinkedIn and on Twitter at: @CytonusTx.
Statements in this news release other than strictly historical facts, such as statements about Cytonus’ plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products, are forward-looking statements. The words “believe,” “expect,” “aim,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. The company undertakes no obligation to publicly update or revise any forward-looking statement. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.
Join Cytonus on LinkedIn and follow its Twitter account at: @CytonusTx
Share article on social media or email: